Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15698812 | 0.81 | KDM4E (0.46) | KDM4EGAAMAPT | |
| SCHEMBL17174358 | 0.77 | DRD1 (0.41) | DRD1 | |
| SCHEMBL17174359 | 0.76 | DRD1 (0.40) | DRD1KDM4EGAAMAPK1 | |
| SCHEMBL15705495 | 0.74 | DRD1 (0.42) | NPSR1DRD1RIPK1KDM4EGAA | |
| SCHEMBL19390564 | 0.74 | SENP1 (0.45) | MAPT | |
| SCHEMBL16687371 | 0.73 | BRD4 (0.42) | MAPTMAPK1 | |
| SCHEMBL17174307 | 0.70 | RIPK1 (0.38) | NPSR1RIPK1KDM4EGAAMAPT | |
| SCHEMBL17174351 | 0.70 | DRD1 (0.40) | NPSR1DRD1SCN5A | |
| SCHEMBL16334643 | 0.70 | DRD1 (0.55) | DRD1KDM4E | |
| SCHEMBL198046 | 0.70 | RIPK1 (0.43) | RIPK1KDM4EMAPTMAPK1SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180200253-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | PFIZER INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180200253-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | PFIZER INC. (US) | 2018-07-19 | — | — | US | disclosed |
| EP-2917219-B1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20170165270-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | PFIZER INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170165270-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | PFIZER INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-9617275-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617275-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150291625-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | PFIZER (US) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180200253-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | COMT, DRD2, NR3C1 | NPSR1 75/4885DRD1 5/4885RIPK1 2011/4885 |
| US-20150291625-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | ARRB1, ADRA1D, ADRB1 | NPSR1 17/4885DRD1 10/4885RIPK1 1229/4885 |
| US-20170165270-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | ARRB1, DRD3, ADRB1 | NPSR1 26/4885DRD1 10/4885RIPK1 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.